The results showed that patients in the high stemness group were more sensitive to the ROCK1 inhibitors GSK269962A and AT1314, implying that these drugs have better therapeutic effects in the overactivation of TGF-β/ROCK1 in BPH. Here, TGFB1 is linked to benign prostatic hyperplasia.